Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.5K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.5K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

1.1K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.1K
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

729
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
729
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

872
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
872
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.0K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.0K
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.1K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recent Pharmacological Guidelines for Difficult-to-Treat Mental Disorders.

Journal of psychosocial nursing and mental health services·2026
Same author

Exploration of Extended-Release Lorazepam: Implications for Safe Nurse Practitioner Practice.

Journal of psychosocial nursing and mental health services·2025
Same author

Improving engagement for enhancing social capital in the older adult: An American Academy of Nursing consensus paper.

Nursing outlook·2025
Same author

Protecting our nursing and healthcare workers with comprehensive strategies for preventing violence and promoting safety: An American Academy of Nursing consensus paper.

Nursing outlook·2025
Same author

Treatment of Attention-Deficit/Hyperactivity Disorder With Stimulants: Reducing Harms.

Journal of psychosocial nursing and mental health services·2025
Same author

Nurses' Roles in Educating and Treating Families of Children and Adolescents Requiring Antipsychotic Treatment: Overcoming Obstacles.

Journal of psychosocial nursing and mental health services·2025

Related Experiment Video

Updated: Mar 6, 2026

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
07:09

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

Published on: July 16, 2014

49.5K

Concerns About Gabapentinoids in Psychiatric Practice.

Karan Kverno1

  • 1Georgetown University Berkley School of Nursing, Washington, D.C.

Journal of Psychosocial Nursing and Mental Health Services
|March 5, 2026
PubMed
Summary

Gabapentinoids, like benzodiazepines, reduce central nervous system hyperexcitability. However, they lack FDA approval for psychiatric disorders, prompting a review of their use, prescribing trends, and safety guidelines for clinicians.

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Gabapentinoids are utilized to mitigate central nervous system hyperexcitability.
  • Benzodiazepines share similar mechanisms but have broader FDA-approved psychiatric indications.

Purpose of the Study:

  • To explore the current landscape of gabapentinoid use in clinical practice.
  • To address concerns and trends associated with gabapentinoid prescribing.
  • To provide guidance for safe clinical decision-making regarding gabapentinoids.

Main Methods:

  • Literature review of gabapentinoid indications.
  • Analysis of prescribing trends and safety data.
  • Synthesis of clinical guidance for healthcare providers.

Main Results:

More Related Videos

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.6K
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

14.3K

Related Experiment Videos

Last Updated: Mar 6, 2026

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
07:09

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

Published on: July 16, 2014

49.5K
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.6K
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

14.3K
  • Gabapentinoids are not FDA-approved for psychiatric disorders, despite their efficacy in conditions with neuronal imbalances.
  • Prescribing trends indicate increasing use, necessitating careful consideration.
  • Clinical guidance is crucial for optimizing patient safety and therapeutic outcomes.

Conclusions:

  • Gabapentinoids present a therapeutic option for hyperexcitability but require cautious application in psychiatric contexts.
  • Further research and clear clinical guidelines are needed to ensure responsible prescribing.
  • Clinicians must weigh benefits against risks, particularly in the absence of specific psychiatric indications.